Loomis, Sayles & Company
TXMD icon

Loomis, Sayles & Company’s TherapeuticsMD TXMD Stock Holding History

Loomis, Sayles & Company’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-13,981
Closed -$2.66M – 874
2018
Q4 		$2.66M Sell
13,981
-779
-5% -$190K 0.01% 463
2018
Q3 		$4.84M Buy
+14,760
New +$4.52M 0.01% 481

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Loomis, Sayles & Company's TXMD Position: Q1 2019 in Review

Loomis, Sayles & Company sold out of TherapeuticsMD (TXMD) in Q1 2019, closing a stake of 13,981 shares — an estimated $2.66M sold.

Loomis, Sayles & Company first reported a position in TXMD in Q3 2018 and held it in 2 quarters. The position peaked at $4.84M in Q3 2018. 146 funds tracked by Wall St. Rank hold TXMD as of Q1 2019.

  • Loomis, Sayles & Company reported no remaining TherapeuticsMD position as of Q1 2019 after selling out during the quarter.
  • Loomis, Sayles & Company sold 13,981 TherapeuticsMD shares in Q1 2019, an estimated $2.66M.
  • Loomis, Sayles & Company first reported a position in TherapeuticsMD in Q3 2018 and held it in 2 quarters.
  • Loomis, Sayles & Company's TherapeuticsMD position peaked at $4.84M in Q3 2018.
  • 146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2019.

Based on Loomis, Sayles & Company's 13F filing for Q1 2019, filed 15 May 2019.